At what enterprise value was HASELMEIER acquired in 2020?

During the acquisition of HASELMEIER by SULZER in 2020, the company was valued at an estimated revenue multiple of below 5x. The transaction's Enterprise Value is estimated to be in the range of 100M - 350M EUR. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 13.4x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of HASELMEIER when it was acquired by SULZER?

The estimated EV/EBITDA multiple for HASELMEIER is in the range of 15x - 25x. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 13.4x. Join our community for free to access full valuation data and industry trends.

When was HASELMEIER acquired by SULZER?

HASELMEIER was acquired by SULZER in 2020.

What was the revenue of HASELMEIER at the time of the deal?

The revenue of HASELMEIER at the time of the deal is estimated to be in the range of 25M - 50M EUR. Register for free to access the full transaction report and exact valuation multiples.

What was the EBITDA of HASELMEIER during the acquisition?

HASELMEIER's EBITDA is estimated to be in the range of 5M - 25M EUR. Join our community for free to access complete and exact deal data.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the HASELMEIER acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the HASELMEIER deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.sulzer.com/en/-/media/files/news/2020/200824_sulzer_to_acquire_haselmeier.pdf

← DATABASE

Home Database Healthcare & PharmaHASELMEIER

10/2020

HASELMEIER

Acquired by

SULZER

SWITZERLAND Life Sciences / Medical Devices / Medical Consumables EV 100M - 350M EUR

HASELMEIER acquired by SULZER

SWITZERLAND Life Sciences / Medical Devices / Medical Consumables EV 100M - 350M EUR

Context

Sulzer has completed the acquisition of Haselmeier, integrating the drug delivery specialist into its Applicator Systems (APS) division. The transaction was structured to acquire 100% of the privately held Swiss-German company, allowing Sulzer to immediately scale its healthcare business and leverage Haselmeier’s significant portfolio of proprietary intellectual property.The strategic rationale for this acquisition is centered on technical synergy and market expansion. By combining Haselmeier’s competence in self-injection devices with Sulzer’s existing expertise in precision injection molding and liquid mixing, the group intends to accelerate the development of innovative and differentiated medical devices. This move allows Sulzer to pivot its APS division toward the high-growth pharmaceutical market, particularly in indications requiring frequent subcutaneous injections. The integration is expected to yield substantial cost synergies through the insourcing of manufacturing processes and the utilization of Sulzer’s global industrial infrastructure.

HASELMEIER, which reported an EBITDA margin of LOGIN in 2019, is valued in this transaction at an EV/EBITDA multiple of LOGIN, representing a LOGIN to the average currently observed in the Healthcare & Pharma sector (13.4x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

Founded in the 20th century, Haselmeier is a leading Swiss-German developer and manufacturer of innovative drug delivery systems, specializing in subcutaneous self-injection devices. The company operates a high-value business model centered on proprietary intellectual property (IP), providing customized solutions such as injection pens for fast-growing medical indications including diabetes, reproductive health, growth disorders, and osteoporosis. Its value proposition lies in its end-to-end service offering, covering the entire product lifecycle from initial design, prototyping, and engineering to industrial-scale production in modern manufacturing facilities. Haselmeier’s strategy emphasizes being a reliable development partner for pharmaceutical companies, offering additional services such as lifecycle management, pharmaceutical packaging, and regulatory support. By focusing on patented platform technologies for injection devices, the company ensures the safe and precise self-administration of liquid drugs, catering to the increasing global demand for home-based healthcare and patient-centric delivery solutions.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2019

2018

Other operations with HASELMEIER

REFERENCES

Valuation range: EV 100M - 350M EUR

Revenue range: 25M - 50M EUR

EBITDA range: 5M - 25M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of HASELMEIER by SULZER are reserved for mynth community members. Register for free to unlock full data.

Authors: mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).